Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.
ASCO Breakthrough Conference
Advertisement
Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.
Advertisement
High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.
Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.
CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.
Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.
Advertisement
Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.
Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC
East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.
Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5